[1] Chinese Society of Infectious Diseases, Chinese Medical Association; Chinese Society of Hepatology, Chinese Medical Association. The guidelines of prevention and treatment for chronic hepatitis B (2019 version). Zhonghua Gan Zang Bing Za Zhi. 2019 Dec 20;27(12):938-961.
[2] TAN Ning, LUO Hao, XU Xiaoyuan. The significance of HBV pgRNA in the process of chronic hepatitis B. Journal of Clinical Hepatology, 2018, 34(10): 189-191.
[3] Chen Jieliang, Wu Min, Liu Kuancheng, et al. New insights into hepatitis B virus biology and implications for novel antiviral strategies. Narnia,2015,2(3).
[4] ZHANG Yuanyuan, WANG Lijuan, XU Yunfang. Characteristics and clinical value of serum HBV pgRNA. Journal of Clinical and Pathological Research, 2020, 40(4): 1018-1022.
[5] Mu, D., et al. Baseline value of intrahepatic HBV DNA over cccDNA predicts patient’s response to interferon therapy. Scientific Reports, 2017. 7(1).
[6] Allweiss L, Dandri M. The Role of cccDNA in HBV Maintenance. Viruses. 2017 Jun 21;9(6):156.
[7] Dong J, Ying J, Qiu X, et al. Advanced Strategies for Eliminating the cccDNA of HBV. Dig Dis Sci. 2018 Jan;63(1):7-15.
[8] Chang J, Guo F, Zhao X, et al. Therapeutic strategies for a functional cure of chronic hepatitis B virus infection. Acta Pharm Sin B. 2014 Aug;4(4):248-57.
[9] LIU RX, PAN XC, GENG J. Clinical value of serum HBV RNA. J Clin Hepatol, 2017, 33(11): 2196-2199.
[10] Giersch K, Allweiss L, Volz T, et al. Serum HBV pgRNA as a clinical marker for cccDNA activity. Journal of hepatology 2017; 66(2): 460-2.
[11] Levrero M, Testoni B, Zoulim F. HBV cure: why, how, when?. Curr Opin Virol. 2016 Jun;18:135-43.
[12] Sarin SK, Kumar M, Lau GK, et al. Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hepatol Int. 2016 Jan;10(1):1-98.
[13] Shen Fang, Li Yaming, Wang Yang, et al. Hepatitis B virus sensitivity to interferon- in hepatocytes is more associated with cellular interferon response than with viral genotype. Hepatology, 2018, 67(4):1237-1252.
[14] Raftery N, Stevenson NJ. Advances in anti-viral immune defence: revealing the importance of the IFN JAK/STAT pathway. Cell Mol Life Sci, 2017, 74(14): 2525-2535.
[15] Chinese Journal of Hepatology, Journal of Clinical Hepatology, Chinese Hepatology. Potential clinical significance of serum HBV RNA virus-like particles. J Clin Hepatol, 2016, 32(9):1635-1636.
[16] Jie Wang, Tao Shen, Xiangbo Huang, et al. Serum hepatitis B virus RNA is encapsidated pregenome RNA that may be associated with persistence of viral infection and rebound. Journal of Hepatology, 2016, 65(4):700-710.
[17] Lin, N., et al. Diagnostic Value of Detection of Pregenomic RNA in Sera of Hepatitis B Virus-Infected Patients with Different Clinical Outcomes. J Clin Microbiol, 2020. 58(2).
[18] Butler, E.K., et al. Hepatitis B Virus Serum DNA andRNA Levels in Nucleos(t)ide Analog-Treated or Untreated Patients During Chronic and Acute Infection. Hepatology, 2018. 68(6): p. 2106-2117.
[19] C.Seeger, W.S.Masson.Hepatitis B Virus biology.Microb.Molec.Biol.Rev, 2000, 64:51-58.
[20] Liu, Y., et al., Serum HBV RNA quantification: useful for monitoring natural history of chronic hepatitis B infection. BMC Gastroenterology, 2019. 19(1).
[21] PENG Y M, YUAN H, ZHOU Y F, et al. Serum hepatitis B virus RNA level in chronic hepatitis B with low level of hepatitis B virus DNA and its influential factors. Chinese General Practice, 2019, 22(18): 2217-2222.
[22] Ching-Chun Yang, et al. Nuclear Export of Human Hepatitis B Virus Core Protein and Pregenomic RNA Depends on the Cellular NXF1-p15 Machinery. PLOS ONE, 2014, 9(10)
[23] Lamontagne RJ, Bagga S, Bouchard MJ. Hepatitis B virus molecular biology and pathogenesis. Hepatoma Res. 2016;2:163-186.
[24] Rokuhara A, Matsumoto A, Tanaka E, et al. Hepatitis B virus RNA is measurable in serum and can be a new marker for monitoring lamivudine therapy. J Gastroenterol, 2006, 41(8): 785-790.
[25] de Niet A, Jansen L, Stelma F, et al. Peg-interferon plus nucleotide analogue treatment versus no treatment in patients with chronic hepatitis B with a low viral load: a randomised controlled, open-label trial. Lancet Gastroenterol Hepatol. 2017 Aug;2(8):576-584.
[26] Thompson AJ, Nguyen T, Iser D, et al. Serum hepatitis B surface antigen and hepatitis B e antigen titers: disease phase influences correlation with viral load and intrahepatic hepatitis B virus markers. Hepatology. 2010 Jun;51(6):1933-44.
[27] LIAO H, WANG J, LU FM. Application value of serum HBV RNA in clinical management of chronic hepatitis B. J Clin Hepatol, 2019, 35(10): 2145-2149.